Navigation Links
Advanced therapy offers cure for relapsed cancer patient

INDIANAPOLIS -- Testicular cancer patients who do not respond to traditional therapy can be cured with high-dose chemotherapy and a stem cell transplant, according to an Indiana University School of Medicine report in the July 26 issue of the New England Journal of Medicine.

About 90 percent of testicular cancer patients respond to traditional therapy, which involves multiple courses of cisplatin, first used successfully in the treatment of this disease by Lawrence Einhorn, M.D., at Indiana University Cancer Center in the early 1980s. That course of therapy turned a disease from a mostly fatal cancer into one of the more curable forms of cancer for men, who typically are in their 20s when diagnosed with testicular cancer.

It is rare for the NEJM to carry a retrospective study from a single institution that is not a randomized study. This review looks at the outcome of 184 patients with metastatic testicular cancer. Dr. Einhorn and colleagues demonstrated that the disease is potentially curable with a high dose chemotherapy and stem cell transplant using cells harvested from the patient before the initial chemotherapy infusion.

The patients received carboplatin chemotherapy at five times the dosage administered to men receiving initial therapy. A side effect of the high dosage is a reduction of blood cells so a stem cell transplant is given to replenish the body’s immune system through a process similar to a blood transfusion. Three to four weeks later the entire process is repeated.

“The message for patients is that through research, diligence and new technologies there is hope,” said Dr. Einhorn, professor of medicine at the Indiana University Melvin and Bren Simon Cancer Center and the lead author of the study. “The bar is steadily being raised and more patients are being saved.”

“This review confirms that high-dose chemotherapy combined with a stem cell transplant can provide a cure for a group of patients with relaps ed testicular cancer,” said Rafat Abonour, M.D., associate professor of medicine in the division of hematology/oncology and associate dean for clinical research at the IU School of Medicine.

Although the number of relapsed testicular cancer patients is small, the IU Simon Cancer Center treats a majority of them. As a leader in this treatment, the researchers were able to collect the necessary data for the NEJM retrospective.

For the patients each year who are treated with this therapy, there is renewed hope. “This is new medicine and it tells patients that cures are on the horizon,” said Stephen D. Williams, M.D., director of the IU Simon Cancer Center and a co-author of the paper.   (Indiana University)


'"/>




Related medicine news :

1. Innovative device aids in advanced heart failure
2. Advanced STD programs required
3. Light therapy devotes new hope in advanced lung cancer
4. Hope For Patients With Advanced Breast Cancer
5. Race an important links to the risk of advanced colorectal cancer
6. HIV Vaccine Field Trials In Advanced Stage
7. Twin Treatment Could Be Used Increase Survival Rates In Advanced Melanoma
8. NICE supports application of advanced biological therapies as treatment option for acute psoriasis
9. Eddie Thompson Receives Advanced Cancer Treatment
10. PSA Can Predicts The Treatment Response In Advanced Prostate Cancer
11. Rapid Aging of Arteries In People With Advanced Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/5/2016)... UT (PRWEB) , ... February 05, 2016 , ... Today, ... Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy ... Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank ...
(Date:2/5/2016)... MN (PRWEB) , ... February 05, 2016 , ... The ... at the Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund ... Larry Schneiderman, owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and Heather ... Napa Valley office. The technique utilizes the body’s own healing abilities to quickly ... Furnas, are part of only a select few cosmetic surgeons bringing this procedure ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe A. ... a joint enrollment and degree completion agreement. The agreement, which begins with ... at FHU|Dickson. , The agreement allows students to be jointly admitted to ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... Wine Tasting Event at the La Gorce Country Club in Miami Beach on ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
Breaking Medicine Technology: